GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Shiller PE Ratio

Anavex Life Sciences (STU:12X1) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anavex Life Sciences Shiller PE Ratio Historical Data

The historical data trend for Anavex Life Sciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anavex Life Sciences Shiller PE Ratio Chart

Anavex Life Sciences Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anavex Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anavex Life Sciences's Shiller PE Ratio

For the Biotechnology subindustry, Anavex Life Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anavex Life Sciences's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Shiller PE Ratio falls into.



Anavex Life Sciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anavex Life Sciences's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Anavex Life Sciences's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.12/131.7762*131.7762
=-0.120

Current CPI (Mar. 2024) = 131.7762.

Anavex Life Sciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.088 100.560 -0.115
201409 -0.667 100.428 -0.875
201412 -0.049 99.070 -0.065
201503 -0.111 99.621 -0.147
201506 -0.196 100.684 -0.257
201509 -0.149 100.392 -0.196
201512 -0.110 99.792 -0.145
201603 -0.054 100.470 -0.071
201606 -0.053 101.688 -0.069
201609 -0.160 101.861 -0.207
201612 -0.076 101.863 -0.098
201703 -0.037 102.862 -0.047
201706 -0.080 103.349 -0.102
201709 -0.101 104.136 -0.128
201712 -0.076 104.011 -0.096
201803 -0.089 105.290 -0.111
201806 -0.051 106.317 -0.063
201809 -0.111 106.507 -0.137
201812 -0.132 105.998 -0.164
201903 -0.133 107.251 -0.163
201906 -0.115 108.070 -0.140
201909 -0.100 108.329 -0.122
201912 -0.108 108.420 -0.131
202003 -0.109 108.902 -0.132
202006 -0.098 108.767 -0.119
202009 -0.085 109.815 -0.102
202012 -0.099 109.897 -0.119
202103 -0.101 111.754 -0.119
202106 -0.116 114.631 -0.133
202109 -0.128 115.734 -0.146
202112 -0.124 117.630 -0.139
202203 -0.127 121.301 -0.138
202206 -0.151 125.017 -0.159
202209 -0.182 125.227 -0.192
202212 -0.160 125.222 -0.168
202303 -0.159 127.348 -0.165
202306 -0.129 128.729 -0.132
202309 -0.122 129.860 -0.124
202312 -0.101 129.419 -0.103
202403 -0.120 131.776 -0.120

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anavex Life Sciences  (STU:12X1) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anavex Life Sciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Anavex Life Sciences (STU:12X1) Business Description

Traded in Other Exchanges
Address
630 5th Avenue, 20th Floor, New York, NY, USA, 10111
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines